IONSYS Drug Patent Profile

When do Ionsys patents expire, and when can generic versions of Ionsys launch?

Ionsys is a drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty-six patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this compound. Additional details are available on the fentanyl hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ionsys

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IONSYS

International Patents:	86
US Patents:	7
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IONSYS

IONSYS is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y

International Patents for IONSYS

When does loss-of-exclusivity occur for IONSYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

India

Israel

Japan

Mexico

New Zealand

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IONSYS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2346599
European Patent Office	0836511	DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE FENTANYL ET DE SUFENTANIL PAR ELECTROTRANSPORT (DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL)
Denmark	1135188
Russian Federation	2014151720	САМОТЕСТИРОВАНИЕ ДЛЯ ОБЕЗБОЛИВАЮЩЕГО СРЕДСТВА (SELF-TEST FOR PAIN-KILLER)
France	2734729	DISPOSITIF POUR L'ADMINISTRATION TRANSDERMIQUE, PAR TRANSFERT ELECTRIQUE, DE FENTANYL OU DE SUFENTANIL
Russian Federation	2557690	СПОСОБ И СХЕМА ПРОВЕРКИ ИСПРАВНОСТИ ВЫКЛЮЧАТЕЛЯ (METHOD AND CIRCUIT FOR TESTING SWITCH SERVICEABILITY)

Supplementary Protection Certificates for IONSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
1635783	300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
0975367	122011000009	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0836511	CA 2006 00019	Denmark		PRODUCT NAME: FENTANYL HYDROCHLORID

Last updated: February 3, 2026

mmary:
IONSYS (fentanyl iontophoretic transdermal system) is a prescription pain management device by AcelRx Pharmaceuticals used for short-term postoperative pain. Its market prospects depend on regulatory approvals, competitive landscape, reimbursement policies, and clinical adoption. The drug's fundamentals reveal limited sales data but demonstrate ongoing development and regulatory engagement. Investment decisions hinge on regulatory outcomes, patent protections, and competitive positioning.

---

What Is the Market Position and Commercial Potential of IONSYS?

IONSYS targets acute postoperative pain management by delivering fentanyl via a transdermal system. Its approval by the FDA in 2012 for adult patients in hospitals and ambulatory settings provided initial market access. The device’s adoption has been incremental, constrained by competition from IV opioids, patient preferences, and hospital formularies.

Market analysts project that the global post-operative pain management market could reach $8-10 billion by 2025. IONSYS's share remains small, partly due to reimbursement hurdles and limited awareness. The device’s price is approximately $100 per patch, with usage frequency typically limited to 24-72 hours.

Sales trajectory: AcelRx reported US sales of approximately $2.7 million in 2020, representing modest commercialization. The company has minimal international sales due to limited approvals outside the US and Europe.

Market penetration factors:

• Reimbursement policies by Medicare and commercial insurers influence uptake.
• Hospital adoption depends on perceived benefits over IV opioids.
• Competition from other transdermal and IV opioid formulations.

Expected revenue growth remains contingent on expanded clinical trials and formalization of reimbursement pathways.

What Are the Regulatory and Patent Forts and Challenges?

Regulatory status:

• FDA approval (2012) for inpatient postoperative pain.
• Pending or approved in Europe (CE mark), with limited expansion in Asia.
• An FDA Supplemental New Drug Application (sNDA) submitted in 2018 to expand indications and improve device features; decision pending.

Patents:

• Original patents extend to 2028, covering device design and fentanyl delivery mechanisms.
• Patent challenges exist; non-Infringement and patent expiration risks could open generic formulations after 2028.
• AcelRx has filed continuations to extend patent protections, possibly until 2030s, but patent cliffs pose risks for long-term exclusivity.

Regulatory hurdles:

• The agency’s emphasis on overdose risk and misuse opioid mitigation influences approval and label expansion.
• The COVID-19 pandemic slowed clinical and administrative processes, delaying potential new approvals or label updates.

How Competitive Is IONSYS Relative to Alternatives?

Main competitors:

• IV opioid formulations (morphine, hydromorphone) dominate hospital settings.
• Transdermal fentanyl patches (Duragesic) for chronic pain but not acute.
• Non-opioid modalities, including NSAIDs and local anesthetic techniques.

Advantages:

• Rapid fentanyl delivery with controlled dosing.
• Reduces need for IV access, simplifying post-surgical pain control.

Limitations:

• Price premium restricts use in cost-sensitive environments.
• Controlled substance regulations limit outpatient or home use.
• Safety concerns regarding overdose or misuse.

Market positioning: IONSYS appeals in specific settings where IV access is challenging and opioid-sparing is prioritized. Its value remains constrained by clinical familiarity, reimbursement issues, and safety concerns associated with opioid delivery systems.

What Are the Clinical and Commercial Development Strategies?

AcelRx's development pipeline focuses on:

• Expanding indications to include outpatient use.
• Improving device interface for ease of use and tracking.
• Conducting clinical trials to compare efficacy with existing IV therapies.

International markets may open as regulatory pathways clear, particularly in Europe and Asia. However, scant data exists on large-scale adoption or market share expansion.

The company’s strategy emphasizes strategic partnerships, regulatory engagement, and potential new formulations to sustain growth past patent expirations.

How Do Reimbursement and Policy Frameworks Impact IONSYS?

Reimbursement policies in the US impact adoption. Medicare and Medicaid often restrict or limit coverage for opioid devices due to opioid misuse concerns. Private insurers may require prior authorization, further slowing uptake.

Legislation around opioid prescribing and abuse deterrence has led to stricter controls, impacting devices like IONSYS. Future policies could either hinder or facilitate adoption, depending on how they address opioid misuse.

What Is the Investment Outlook Based on Financials and Market Trends?

Limited revenues and ongoing clinical and regulatory efforts portray IONSYS as a high-risk, early-stage asset. Its valuation heavily depends on successful expansion, positive reimbursement decisions, and safety profile improvements.

AcelRx's cash runway and partnership initiatives will influence its capacity to sustain development. Investors should monitor:

• Upcoming regulatory decisions, especially regarding label expansions.
• Competitive landscape shifts and new entrants to post-operative pain devices.
• Policy environment changes affecting opioid use in hospitals.

---

Key Takeaways

• IONSYS has a niche position in acute postoperative pain but suffers from limited sales, reimbursement barriers, and stiff competition.
• Patent protections extend until 2028, with ongoing efforts to extend or defend exclusivity.
• Market expansion depends on clinical trial results, regulatory approvals outside the US, and reimbursement landscape evolution.
• Competitive disadvantages include high device cost and safety concerns related to opioids.
• Long-term valuation relies on successful indication expansion, safety improvements, and greater integration into hospital pain protocols.

---

FAQs

1. What are the main barriers to IONSYS’s widespread adoption?
Reimbursement restrictions, safety concerns over opioids, competition from established IV therapies, and limited clinical awareness hinder broad adoption.

2. How long does patent protection for IONSYS last?
Patents are valid until approximately 2028, with ongoing patent filing efforts potentially extending exclusivity into the 2030s.

3. Are there regulatory risks for IONSYS’s future approval expansions?
Yes. The FDA emphasizes safety and misuse mitigation for opioids, which could lead to delays or restrictions in expanding indications.

4. How does IONSYS compare cost-wise to alternative pain management options?
It costs approximately $100 per patch, which can be higher than standard IV opioids when considering volume and hospital budgets, limiting its use mainly to specific clinical scenarios.

5. What is the potential for international market growth?
Growth prospects exist in Europe and Asia, especially if regulatory approvals are obtained; however, expansion remains limited by local policies and market awareness.

---

Citations
[1] AcelRx Pharmaceuticals Annual Reports (2020-2022)
[2] U.S. Food and Drug Administration (FDA) approvals and filings
[3] Market research reports on post-operative pain management (2019-2022)